Home
Centre for Cancer Biomarkers CCBIO

News archive for Centre for Cancer Biomarkers CCBIO

CCBIO organized a special session with focus on the transition from a blockbuster to personalised cancer therapy at the S.Net conference recently held in Bergen.
11th October, CCBIO hosted a pre-conference event on the Ethical and Social Aspects of Cancer Research as part of the S.Net conference, of the Society for the Study of New and Emerging Technologies.
Medical research student (Forskerlinjestudent) Amalie A. Svanøe was awarded with 3rd best oral presentation at joint International Congress of the International Academy of Pathology and the European Congress of Pathology, which took place in Cologne, Germany, September 25-29, 2016.
September 14th, CCBIO, the Department of Clinical Science at UiB and the Women's Clinic at Helse Bergen organized a memorial symposium for Helga B. Salvesen, the CCBIO cancer researcher who passed away in January this year. People came from far and near to be together at this scientific gathering.
CCBIO Director Lars A. Akslen and CCBIO affiliated Arne Östman from Karolinska Institutet initiated and chaired The First Scandinavian Seminar on Translational Pathology. Approximately 50 cancer researchers gathered in the wild west of Sotra at Panorama Hotel outside of Bergen.
A new study suggests that reconstruction of breast affects recurrence of breast cancer, and actually reduce time to relapse of the disease. The study was recently presented as front page news in the journal Breast Cancer Research and Treatment, with main author Hanna Dillekås who is PhD candidate at Professor Oddbjørn Straumes group. Straume is CCBIO PI and also last author of the study.
A publication in PNAS by researchers from the Department of Clinical Science and CCBIO was selected to be highlighted in the Editors' Choice section of Science Signaling, the weekly journal from the publisher of Science magazine, and has been selected for an Editorial feature that will be published in the journal Cell Cycle.
The BTO project CryoIT has received 10 million NOK from the Research Council of Norway’s FORNY2020 program. The project develops a new form of immunotherapy against prostate cancer, called cryoimmunotherapy, which can also be adapted to treat different types of cancer. The project belongs to Haukeland University Hospital and the University of Bergen.
Outside the birds are twittering in the warm sun. Inside are cold facts on biomarkers and immuno therapy, including research which may lead to cancer testing through urine samples. CCBIO's Annual Symposium offers a widespread program.
Henrica Werner received the 2015 Young Researcher Award from Onkologisk Forum. "The hope to give patients the for them correct treatment from the start, avoiding unnecessary side effects and ‘right-treatment delay’ in future through development of both prognostic and predictive biomarkers is what drives me", says the CCBIO postdoc and gynaecologist in an interview.
Have you ever struggled to cope with the complexity of cancer biology, while also trying to produce results that are relevant for the research community? Or maybe you've thought about the difficult gap between patients' expectations and what your science can actually provide?
CCBIO PI Lars A. Akslen and Postdoc Anna Blois (shared 1st author) are collaborators in a recently published study which shows that small peptides attack ovarian cancer on 2 fronts.
Professor Kreyberg's Prize is awarded every leap year day to the best dissertation in the field of pathology during the last 4 years. An award of NOK 100.000 goes this year to Dr.Med. Elisabeth Wik, Fellow at the Department of Clinical Medicine and CCBIO Postdoc.
14-15 January 2016, Roger Strand (SVT and CCBIO) took part in two events organized by the Initiative for the Humanistic Study of Innovation at Indiana University in Bloomington, US.
Helse Vest's Research Prize was this year awarded to the Gynaecologic Research Group led by CCBIO PI Helga B. Salvesen. The Innovation Award went to James Lorens at BerGenBio and UiB, also CCBIO PI.
Perhaps we should issue a time frame on the public health bureaucracy, says CCBIO Director Lars A. Akslen, when considering the time it takes new drugs to be accepted to Norway.
CCBIO applied for 4,5 million NOK over 3 years and has now been granted INTPART-funding from the Norwegian Research Council (RCN) and the Norwegian Centre for International Cooperation in Education (SIU).
At this semester’s first CCBIO Junior Scientist Symposium September 17th, there was again large interest in participating at the seminar. More than 40 registered for the whole seminar and even more participated at selected presentations.

Pages